Liang Zhao, PhD, is a leading innovator in immuno‑metabolism and anti‑tumor drug discovery, known for pioneering metabolomics‑driven insights that have advanced cancer biology and therapeutic development. Trained as an analytical chemist, he launched his career at Johns Hopkins University, where he co‑founded the first metabolomics core facility at the Bloomberg School of Public Health and later directed the immuno‑metabolism mass spectrometry laboratory at the Sidney Kimmel Comprehensive Cancer Center.
At Hopkins, Dr. Zhao developed cutting‑edge stable‑isotope tracing technologies that uncovered distinct metabolic and lipidomic programs in cancer and immune cells. His work has generated more than 100 publications in top journals—including Nature, Science, and Nature Immunology—highlighted by a landmark 2019 Science study revealing the mechanism of a glutamine‑antagonist anti‑tumor therapy.
Since 2023, Dr. Zhao has served as Vice President of Metabolomics at Complete Omics, integrating mass spectrometry, molecular biology, and AI to drive innovation in metabolomics‑based biomarkers, precision diagnostics, and metabolic‑targeted cancer therapeutics.
Ibelieve metabolomics represents the next frontier of precision medicine—capturing the real-time functional state of biology and revealing how cells dynamically respond to disease, immunity, and therapy. By quantifying metabolic flux and pathway activity at scale, we can translate complex biochemical networks into actionable, clinically meaningful insights.
At Complete Omics, my focus is to integrate advanced metabolomics platforms and computational intelligence into standardized, clinically adaptable workflows. Our goal is to translate multi-omics discoveries into practical diagnostics and therapeutics—converting pathway signatures into robust biomarkers and AI-driven decision tools.
Biography
Pioneering leaders in clinical proteomics, translating deep scientific innovation into robust, clinically deployable assays.
Contact Form